PubRank

Kent H Summers

Author PubWeight™ 24.77‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Diabetic retinopathy: contemporary prevalence in a well-controlled population. Diabetes Care 2003 1.84
2 Relationships between hyperglycemia and cognitive performance among adults with type 1 and type 2 diabetes. Diabetes Care 2005 1.75
3 A comparison of clinical practice guidelines in the initial pharmacological management of new-onset epilepsy in adults. J Manag Care Pharm 2006 1.59
4 Prevalence of exposure to potential CYP450 pharmacokinetic drug-drug interactions among patients with chronic low back pain taking opioids. Pain Pract 2010 1.46
5 Productivity and medical costs of diabetes in a large employer population. Diabetes Care 2002 1.30
6 Cost and utilization comparisons among propensity score-matched insulin lispro and regular insulin users. J Manag Care Pharm 2003 1.23
7 Quality of life of women with urinary incontinence: cross-cultural performance of 15 language versions of the I-QOL. Qual Life Res 2005 1.19
8 Exposure to potential CYP450 pharmacokinetic drug-drug interactions among osteoarthritis patients: incremental risk of multiple prescriptions. Pain Pract 2010 1.02
9 A comparison of daily average consumption (DACON) of oxycodone and oxymorphone long-acting oral tablets. J Manag Care Pharm 2011 1.01
10 Development of an instrument to assess expectations of and preference for an insulin injection pen compared with the vial and syringe. Clin Ther 2004 0.94
11 Clinical practice guidelines on the initial assessment and treatment of urinary incontinence in women: a US focused review. Int J Gynaecol Obstet 2004 0.91
12 Pharmaceutical manufacturer prescription assistance programs: are they worth it? J Manag Care Pharm 2007 0.90
13 Predicting EQ-5D utility scores from the 25-item National Eye Institute Vision Function Questionnaire (NEI-VFQ 25) in patients with age-related macular degeneration. Qual Life Res 2009 0.88
14 Economic impact of potential CYP450 pharmacokinetic drug-drug interactions among chronic low back pain patients taking opioids. Pain Pract 2011 0.84
15 The prevalence of opioid-related major potential drug-drug interactions and their impact on health care costs in chronic pain patients. J Manag Care Spec Pharm 2014 0.80
16 Estimated economic benefits from low-frequency administration of atypical antipsychotics in treatment of schizophrenia: a decision model. Ann Gen Psychiatry 2012 0.80
17 Comparison of costs and utilization between users of insulin lispro versus users of regular insulin in a managed care setting. J Manag Care Pharm 2005 0.79
18 Development of a men's Preference for Testosterone Replacement Therapy (P-TRT) instrument. Patient Prefer Adherence 2012 0.78
19 Pharmacist intervention in safe and effective conversion of brand to generic drugs. J Manag Care Pharm 2005 0.78
20 Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin. J Med Econ 2010 0.78
21 Economic impact of potential drug-drug interactions among osteoarthritis patients taking opioids. Pain Pract 2011 0.78
22 Development of a questionnaire to assess the impact of chronic low back pain for use in regulated clinical trials. Patient 2013 0.78
23 Economic implications of potential drug-drug interactions in chronic pain patients. Expert Rev Pharmacoecon Outcomes Res 2013 0.77
24 Descriptive analysis of Medicaid patients with postherpetic neuralgia treated with lidocaine patch 5%. J Med Econ 2010 0.76
25 Challenges and opportunities in pharmacogenomics and therapeutics. J Manag Care Pharm 2007 0.75
26 Health utility and economic analysis: theoretical and practical issues. Expert Rev Pharmacoecon Outcomes Res 2009 0.75
27 Direct and indirect costs of patients treated with extended-release oxymorphone HCl or controlled-release oxycodone HCl. J Med Econ 2011 0.75
28 Use of economic models in formulary decisions. Expert Rev Pharmacoecon Outcomes Res 2002 0.75